Full text is available at the source.
Abstract
Psilocybin may serve as a novel therapy for major depression, with a clinical study planned to assess its safety and efficacy.
- Psilocybin is derived from mushrooms endemic to Mexico and shows potential as a treatment for major depression.
- The study includes a preclinical evaluation of toxicity and pharmacological effects using mice.
- A clinical trial will assess the safety and efficacy of psilocybin compared to traditional care in patients with major depressive disorder.
- Safety evaluations will focus on tolerated doses and pharmacokinetic parameters after oral administration in healthy adults.
- The research design involves fully characterizing the mushroom extract before clinical application.
Simplified